Educational Videos

ACR/VF Guidelines Conference Videos

General Session One: Part 1
Introducing the 2021 ACR/VF Vasculitis Clinical Practice Guidelines

Sharon A. Chung, MD, MAS
Director, Vasculitis Clinic, UCSF
San Francisco, California

General Session One: Part 2
Introducing the 2021 ACR/VF Vasculitis Clinical Practice Guidelines: Q&A with Dr. Sharon Chung

General Session Two: Disseminating the Guidelines to Healthcare Professionals

Carol A. Langford, MD, MHS, FACP
Director, Center for Vasculitis Care and
Research, Cleveland Clinic, Cleveland, Ohio

2021 Virtual ACR/VF Patient Treatment Conference Breakout Sessions

Giant Cell Arteritis (GCA) Breakout Session

Historical Accounts of GCA 4:02
2012 Revised International Chapel Hill Consensus Conference (CHCC2012) Nomenclature of Vasculitides 5:28
CHCC2012 definition of GCA 6:41
Therapy Definitions 8:56
GCA Case: Initial Presentation 11:09
Diagnostic Testing Recommendations 14:17
Medical Management Recommendations 26:29
Trial of Tocilizumab in GCA 31:44
GCA Case: New Visual Symptoms 34:18
Surgical Intervention Recommendations 38:00
GCA Case: The Challenge of Inflammatory Markers 40:47
Clinical / Laboratory Monitoring Recommendations 41:43
GCA Case: Relapse 42:26
Medical Management Recommendations: Add Statins? 46:00
GCA Case: Long Term Monitoring 48:12
Duration of Therapy Upgraded Position Statement 49:50

Mehrdad Maz, MD
Director, Allergy, Clinical Immunology
and Rheumatology, Kansas University,
Kansas City, Kansas

Rennie Rhee, MD,
University of Pennsylvania Vasculitis Center,
Philadelphia, Pennsylvania

Polyarteritis Nodosa (PAN) Breakout Session

Polyarteritis Nodosa (PAN) Quick Facts 2:41
Important Considerations for the Recommendations 6:40
Guideline Methods 7:39
PAN Case One 9:56
Diagnostic Challenges: The Skin Biopsy 10:32
Skin Biopsy: Deep vs. Punch 11:45
Diagnostic Challenges: The Nerve Biopsy 13:24
Abdominal Vascular Imaging 17:24
Treatment Phases 20:15
Treatment After Remission 22:29
Treatment with Physical Therapy 24:59
Q&A: Do these guidelines cover systemic and cutaneous PAN? 30:40
Q&A: Do the recommendations cover the use of Rituximab with PAN? 31:29
Q&A: Was it a challenge to find clinical study information on PAN to use in considering recommendations? 35:43
Q&A: What is recommendation if patient fails Cellcept and is having a liver problem? Is Rituximab an option? 38:49
Q&A: What do recommendations say about how long a patient has to remain on immunosuppressants or steroids once he/she is in remission? 42:27
Q&A: Could you share the 2-3 most important recommendations for PAN? 45:16
Q&A: Do the recommendations address the issue of using imaging to monitor long-term damage caused to the arteries. 48:32

Jason A. Springer, MD, MS
Co-Director, Vanderbilt Vasculitis Center,
Nashville, Tennessee

Yih Chang Lin, MD
University of South Florida Vasculitis Center
Tampa, Florida

Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Breakout Session

Overview of GPA and MPA 1:56
A Patient Case 4:07
General Treatment Strategy: active, severe GPA/MPA 5:48
Question: What medication should this patient receive for remission induction? 6:59
Reduced vs. Standard Dosing Regimen 10:16
What About Other Remission Maintenance Agents? 15:14
Preferences for Remission Induction and Maintenance Therapy in Severe GPA/MPA 16:29
What Therapy If Relapse Occurs? 25:14
What About ANCA Titers? 28:06
What About Combination Drive? 35:35
Other Interventions About Sinus Symptoms? 37:41
Avacopan. 39:44
Q: Could you talk more about ANCA-titers, and B-Cell Monitoring? 44:51
Q: What research or knowledge gaps did you find related to GPA and MPA? 51:23
Q: Do the ACR/VF Guidelines address biosimilars? 53:42
Q: Any comments or concerns about the COVID vaccines triggering an autoimmune response? 54:54

Sharon A. Chung, MD, MAS Director, Vasculitis
Clinic, UCSF
San Francisco, California

Kevin W. Byram, MD
Co-Director, Vanderbilt Vasculitis Clinic,
Nashville, Tennessee

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Breakout Session

Overview of EGPA 2:10
ACR / VF Guideline for the Management of EGPA 3:25
Recommendations on the Treatment of EGPA 5:03
Q&A: Is being ANCA negative a good thing, or a bad thing? 19:44
Q&A: Could you comment on what the guidelines say about Leukotriene inhibitors? 22:24
Q&A: What is the role for Avocopan in EGPA? 24:00
Q&A: Can you comment on the recommendation about having an echocardiogram at the time of diagnosis? 27:48
Q&A: Do the guidelines take a stand on the use of Mepolizumab? Is this the drug of choice? 30:59
Q&A: Are there still patients for whom you would recommend the use of Cyclophosphamide over Rituximab? 32:47
Q&A: Do you have a favorite guideline? 35:10
Q&A: Do you think there are particular guidelines that will be ripe of review in the future? 37:25
Q&A: Do you have an opinion on the role of IVIG and whether it’s indicated, or contradicted in EGPA? 39:08
Q&A: Can you comment on the role of pneumocystis prophylaxis?
Q&A: What do you see as the most urgent clinical need for EGPA? 45:14
Q&A: If a patient has EGPA is there any concern that someone else in their family could also get it, or a form of vasculitis? 46:14
Q&A: Do all flares in EGPA associate with increases in eosinophils count? 49:23

Carol A. Langford, MD, MHS, FACP
Director, Center for Vasculitis Care and
Research, Cleveland Clinic, Cleveland, Ohio

Phil Seo, MD
Director, Johns Hopkins Vasculitis Center,
Baltimore, Maryland

Takayasu Arteritis (TAK)

What is Takayasu Arteritis (TAK)? 0:24
TAK ACR Classification Criteria. 1:47
What makes TAK difficult? 2:30
A TAK Case Presentation. 3:18
Using non-evasive imagine over cathedar-based dye angiography as assessment tool. 4:07
What to do in cases of active, severe takayasu arteritis. 4:57
Non-GC Immunosuppressive Agents. 5:39
Overview of how to treat active Takayasu Arteritis. 7:01
Refractory disease–Biologics. 8:02
Monitoring Takayasu Arteritis–Clinical. 9:26
Monitoring Takayasu Arteritis–Labs 10:17
Adding inflammatory markers. 10:19
Recommend regularly scheduled non-invasive imaging. 10:57
Goal: Steroids =0. 12:26
Surgical intervention. 15:45
Refractory disease and surgical intervention. 16:36
Special considerations: TAK and pregnancy. 19:47
Key points summary. 21:17

Anisha Dua, MD, MPH
Director, Northwestern Vasculitis Center, Chicago, Illinois